Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

Drotrecogin alfa (activated) is approved for use in patients with sepsis who are at high risk for death. This controlled trial found no benefit in patients at a low risk for death (relative risk of death with drotrecogin alfa, 1.08). The rate of serious bleeding was higher with drotrecogin alfa. Dro...

Full description

Bibliographic Details

Main Authors:	Abraham, Edward P. (Author) , Laterre, Pierre-François (Author) , Garg, Rekha (Author) , Levy, Howard (Author) , Talwar, Deepak (Author) , Trzaskoma, Benjamin L. (Author) , François, Bruno (Author) , Guy, Jeffrey S. (Author) , Brückmann, Martina (Author) , Rea-Neto, Álvaro (Author) , Rossaint, Rolf (Author) , Perrotin, Dominique (Author) , Sablotzki, Armin (Author) , Arkins, Nancy (Author) , Utterback, Barbara G. (Author) , Macias, William L. (Author)
Format:	Article (Journal)
Language:	English
Published:	September 29, 2005
In:	The New England journal of medicine Year: 2005, Volume: 353, Issue: 13, Pages: 1332-1341
ISSN:	1533-4406
DOI:	10.1056/NEJMoa050935
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa050935
Author Notes:	Edward Abraham, M.D., Pierre-François Laterre, M.D., Rekha Garg, M.D., Howard Levy, M.D., Ph.D., Deepak Talwar, M.D., Benjamin L. Trzaskoma, M.S., Bruno François, M.D., Jeffrey S. Guy, M.D., Martina Brückmann, M.D., Álvaro Rea-Neto, M.D., Rolf Rossaint, M.D., Dominique Perrotin, M.D., Armin Sablotzki, M.D., Ph.D., Nancy Arkins, R.N., Barbara G. Utterback, M.S., M.B.A., and William L. Macias, M.D., for the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group